Evidence map›Paper›PMID 31466948›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019

Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.

Erik J Snider, Griselda Compres, Daniel E Freedberg, Hossein Khiabanian, Yael R Nobel, Stephania Stump, Anne-Catrin Uhlemann, Charles J Lightdale, Julian A Abrams

Registry-linked trialAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05412628 (Investigating the Association, Disease Mechanism, and Clinical Application Between Microbiota and Oropharyngeal and Esophageal Cancer), which is not on this map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05412628 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Investigating the Association, Disease Mechanism, and Clinical Application Between Microbiota and Oropharyngeal and Esophageal Cancer

TypeinterventionalSponsorNational Cheng-Kung University HospitalRan2022 to 2024Enrolled60ConditionsMicrobial Colonization, Esophageal Cancer, Oropharyngeal Neoplasms, Synchronous NeoplasmArmsOral swab test
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Esophageal microbiota composition and outcome of esophageal cancer treatment: a systematic review.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Virulence · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Big lessons from the littleFrontiers in immunology · 2025
    Review
  20. Review

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erik J SniderDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington.
Griselda CompresDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Daniel E FreedbergDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Hossein KhiabanianRutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.ORCID 0000-0003-1446-4394
Yael R NobelDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0001-5759-3730
Stephania StumpDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Anne-Catrin UhlemannDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0002-9798-4768
Charles J LightdaleDepartment of Medicine, Columbia University Irving Medical Center, New York, New York.
Julian A AbramsDepartment of Medicine, Columbia University Irving Medical Center, New York, New York. ja660@cumc.columbia.edu.

Funding

Weight loss-induced Microbiome and Adipokine Changes in Barrett's EsophagusU54CA163004 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABRAMS, JULIAN, RUSTGI, ANIL K · 2011 to 2022
$12.5M
Carbapenem-resistant bacterial colonization and infection after liver transplantR01AI116939 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI UHLEMANN, ANNE-CATRIN · 2015 to 2019
$2.4M
Loss of Gastrointestinal Colonization Resistance and Antibiotic-Resistant Infections in the Intensive Care UnitK23DK111847 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FREEDBERG, DANIEL E. · 2017 to 2020
$608k
NCI NIH HHS U54 CA163004NIAID NIH HHS R01 AI116939NIDDK NIH HHS K23 DK111847
6 · The paper itself

Abstract

backgroundThe incidence of esophageal adenocarcinoma has risen dramatically over the past half century, and the underlying reasons are incompletely understood. Broad shifts to the upper gastrointestinal microbiome may be partly responsible. The goal of this study was to describe alterations in the esophageal microbiome that occur with progression from Barrett's esophagus to esophageal adenocarcinoma.

methodsA case-control study was performed of patients with and without Barrett's esophagus who were scheduled to undergo upper endoscopy. Demographic, clinical, and dietary intake data were collected, and esophageal brushings were collected during the endoscopy. 16S rRNA gene sequencing was performed to characterize the microbiome.

resultsA total of 45 patients were enrolled and included in the analyses [16 controls; 14 Barrett's esophagus without dysplasia (NDBE); 6 low-grade dysplasia (LGD); 5 high-grade dysplasia (HGD); and 4 esophageal adenocarcinoma]. There was no difference in alpha diversity between non-Barrett's esophagus and Barrett's esophagus, but there was evidence of decreased diversity in patients with esophageal adenocarcinoma as assessed by Simpson index. There was an apparent shift in composition at the transition from LGD to HGD, and patients with HGD and esophageal adenocarcinoma had decreased Firmicutes and increased Proteobacteria. In addition, patients with HGD or esophageal adenocarcinoma had increased

conclusionsShifts in the Barrett's esophagus-associated microbiome were observed in patients with HGD and esophageal adenocarcinoma, with increases in certain potentially pathogenic bacteria. IMPACT: The microbiome may play a role in esophageal carcinogenesis.

Indexed as

MicrobiotaAdenocarcinomaBacteriaBarrett EsophagusDisease ProgressionEsophageal NeoplasmsFemaleHumansMaleMiddle AgedPrecancerous ConditionsPrognosis

Identifiers

PMID31466948
PMCPMC6774849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.